ONCOZENGE Aktie

 

OncoZenge AB (publ) (“OncoZenge” or “the Company”), a pharmaceutical company developing an innovative treatment for oral pain relief held a Capital Markets Day on 18 September 2025. The on-demand video from the event is now available. The investor event was held in collaboration with Redeye and featured key topics such as... · Company strategy, priorities and financing presented by Stian Kildal, CEO.  · The BupiZenge™ Phase III program and timeline presented by Christina Junvik, Head of Regulatory. · Stephen Sonis, DMD, DMSc introduced cancer therapy toxicities and unmet needs,...

STOCKHOLM, Sept. 17, 2025 /PRNewswire/ -- OncoZenge AB (publ) ("OncoZenge" or "the Company"), a pharmaceutical company developing an innovative treatment for oral pain relief, today announced a new collaboration with the University of California, Los Angeles (UCLA). The partnership......

OncoZenge AB has selected LINK Medical, a Nordic-based clinical research organization (CRO), to lead the Phase III trial for BupiZenge™, its innovative drug candidate designed to relieve oral pain from mucositis in cancer patients. The program will enroll approximately 150 patients across 10-12 sites in Norway, Sweden, Denmark, and Germany. Patient recruitment and study results are expected in 2026, with the primary focus on reducing patients' pain compared to lidocaine. Secondary endpoints will include quality-of-life measures (e.g., eating ability, sleep), weight as a proxy for oral intake,...

OncoZenge AB (publ), a late-stage pharmaceutical company advancing its lead candidate BupiZenge™ into Phase III execution, is pleased to announce its Capital Markets Day on Thursday, 18 September 2025, in Stockholm, Sweden. The event will offer investors, analysts, and media an in-depth look at OncoZenge's strategic direction, commercial opportunities, and operational milestones. Event Overview The Capital Markets Day will take place from 15:00 to 17:00 CET at Redeye, Mäster Samuelsgatan 42, 10th Floor, Stockholm.  Key highlights include: · Strategy and growth roadmap for...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the second quarter of 2025. The Company's Phase III program has moved into execution. Preparations are now underway for manufacturing of BupiZenge™ clinical trial material. The European site feasibility study is progressing according to plan with positive responses from 12 hospitals in four countries. Summary of the Second Quarter In January, an investment agreement worth SEK 30.2 million was signed with the new strategic investor Sichuan Yangtian Bio-Pharmaceutical Co. Ltd, to be executed through...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today publishes its event calendar for September to December 2025. Schedule priorities highlight OncoZenge's commitment to sharing progress on its Phase 3 program for BupiZenge™, a novel opioid-sparing treatment for oral mucositis pain, while expanding business development and partner engagement efforts for a future USA market entry. Key Events for Fall 2025 OncoZenge will engage with investors, partners, and industry leaders at the following events:   +--------------+------------------------------------+------------------+ |...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces the change to English as reporting language in order to meet the needs of the Company's international investors, partners and stakeholders. In order to effectively meet the needs of the Company's international investors, partners and stakeholders OncoZenge will be reporting financial, regulatory and other information to the market in English. The adoption of financial reporting in English will commence as of the publication of the interim report for the period ending the second quarter of 2025, which will be published on...

OncoZenge AB (publ) (“OncoZenge” or “the Company”) today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge™ Phase 3 clinical trial aimed at achieving European Medicines Agency (EMA) approval for the European market. This critical milestone moves OncoZenge closer to establishing BupiZenge™ as the new standard of care for treating the pain caused by oral mucositis. OncoZenge estimates that at least 35% of cancer patients develop oral mucositis after beginning treatment, and most of these patients will experience more effective and...

OncoZenge AB ("OncoZenge" or "the Company") today announced it has engaged Meribel Pharma Solutions ("Meribel," formerly Recipharm) as its Contract Development and Manufacturing Organization (CDMO) for the BupiZenge™ Phase 3 Project. OncoZenge is preparing a multi-country Phase 3 study to secure European approval for BupiZenge™. The project scope has recently been refined in close collaboration with OncoZenge's pan-European licensing partner, Molteni Farmaceutici. The decision to partner with Meribel Pharma Solutions in Sweden was made to leverage their expertise in development and...

OncoZenge AB (publ) (“OncoZenge” or “the Company”) today announced the signing of an amendment to the license and supply agreement with Molteni Farmaceutici. This amendment accelerates certain milestones, totalling €550,000, to 'Clinical Trial Application Approval' with payment of such amount not earlier than March 1st, 2026. This accelerated milestone payment replaces the milestones due upon 'Successful Trial Completion' and 'First Commercial Sale'. The accelerated milestone payment, together with previously announced convertible note financing from Linc AB, enable a strategic shift to...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the initial investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the ”Investor”). On January 27, 2025, OncoZenge announced that the Company had entered into an investment agreement which provides the Investor with a maximum of 4 669 647 shares in the Company subject to an investment amounting to approximately SEK 30.2m. The purpose of the investment is to finance the Company's phase 3 project for BupiZenge™, targeting a European market approval. The investment is to be executed by way of four...

OncoZenge AB (publ) ("OncoZenge" or "the Company") has today entered into an agreement for a bridge financing solution of SEK 7.5 million, via a convertible note with Linc AB ("Linc"). The Company has signed a binding convertible note agreement with one of its major shareholders, Linc. The convertible note encompasses a convertible loan totaling SEK 7.5 million, maturing on July 31, 2027. The convertible loan carries an annual interest rate of 8.00 percent from the time of disbursement. Interest will be capitalized until the time of repayment of the loan, or the time of a potential...

OncoZenge AB (publ) ("OncoZenge" or "the Company") announces today that the sponsor team for the phase 3 project with BupiZenge™ is strengthened by the addition of Tuulikki Lindmark, who joins the Company as responsible for Chemistry, Manufacturing and Controls (CMC). OncoZenge is pleased to welcome Tuulikki Lindmark, with RegSmart Life Science, as CMC responsible for the phase 3 program. In this role, she will lead the collaboration with the CDMO, in preparation for start of production and the regulatory application for the phase 3 study of BupiZenge™. Tuulikki Lindmark brings extensive...

The information contained in this press release is not for publication, release or distribution, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction where such publication or distribution would be contrary to applicable laws or regulations. Please see “Important information” at the end of this press release.   The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or the “Company”) has, based on renewed authorisation granted by the Annual...

OncoZenge AB (publ) ("OncoZenge" or the “Company") has today received confirmation that the State Administration of Foreign Exchange (SAFE) has completed its review of the investment agreement entered into by the Company and Sichuan-Yangtian Biopharmaceuticals Co, Ltd (“Yangtian Pharma” or the “Investor”) on January 27th, 2025. On January 27th the Company announced the intention to partner with Yangtian Pharma as a new strategic investor in the Company, by entering into an investment agreement that through four tranches of directed share issues to Yangtian Pharma will provide the financing...

OncoZenge AB (publ) (”OncoZenge” or “the Company”) announces that the Company's board member and Chief Medical Officer Dr. Chris Nowak, will present the study design for the planned registrational Phase 3 study of BupiZenge™ at the Multinational Association of Supportive Care in Cancer (MASCC) / International Society of Oral Oncology (ISOO) Annual Meeting 2025 in Seattle, Washington, USA. The study aims to compare BupiZenge™ with the current standard of care for treating pain caused by oral mucositis in cancer patients. The oral presentation will take place within the Cancer Pain section on...

OncoZenge AB (publ) ("OncoZenge" or the “Company") has today received confirmation that the Department of Commerce has issued a certificate of approval for the investment agreement entered into by the Company and Sichuan-Yangtian Biopharmaceuticals Co, Ltd (“Yangtian Pharma” or the “Investor”) on January 27th, 2025. On January 27th the Company announced the intention to partner with Yangtian Pharma as a new strategic investor in the Company, by entering into an investment agreement that through four tranches of directed share issues to Yangtian Pharma will provide the financing for the phase...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that LINK Medical has been engaged to conduct a feasibility study in Europe for the Company's planned Phase 3 study for European approval of BupiZenge™. OncoZenge is planning a multi-country Phase 3 study for the approval of BupiZenge™ in Europe. The scope of the Phase 3 study has been updated in recent weeks in close collaboration with the Company's licensing partner, Molteni Farmaceutici. As part of the planning and to optimize lead-times, the Company has engaged LINK Medical to perform a feasibility study for the European...

OncoZenge AB (publ) ("OncoZenge" or the “Company") today provides an update on the status of the regulatory process in China for the investment agreement entered into by the Company and Sichuan-Yangtian Biopharmaceuticals Co, Ltd (“Yangtian Pharma” or the “Investor”) on January 27th, 2025. The filing is currently in review with the provincial Department of Commerce, and the necessary documentation has been provided to the counterparty bank appointed by the State Administration of Foreign Exchange. On January 27th the Company announced the intention to partner with Yangtian Pharma as a new...

OncoZenge AB (publ) ("OncoZenge" or the “Company") has today received confirmation that the NDRC has issued a certificate of approval for the investment agreement entered into by the Company and Sichuan-Yangtian Biopharmaceuticals Co, Ltd (“Yangtian Pharma” or the “Investor”) on January 27th, 2025. On January 27th the Company announced the intention to partner with Yangtian Pharma as a new strategic investor in the Company, by entering into an investment agreement that through four tranches of directed share issues to Yangtian Pharma will provide the financing for the phase 3 trial for...